Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers

Conditions: Monoclonal Gammopathy of Uncertain Significance, Smoldering Myeloma

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: NA

Enrollment: 67

Sponsor: Hackensack Meridian Health

Summary

A prospective, pilot study to assess the impact of a 12-month multi-focal lifestyle intervention on myeloma-relevant biomarkers in patients with MGUS or SM. The multimodal lifestyle intervention has six foci that patients will participate in over the course of one-year.

Eligibility Criteria

Inclusion Criteria: * Adults 18 years or older. * Diagnosed with MGUS or SM based on commonly accepted criteria per the International Multiple Myeloma Working Group (IMWG), defined as follows: a. For a diagnosis of Smoldering Multiple Myeloma (SM), both criteria must be met: i. Serum monoclonal protein (IgG or IgA) ≥ 30g/L or urinary monoclonal protein ≥ 500mg per 24h and/or clonal bone marrow plasma cells 10-60% ii. Absence of myeloma-defining events or amyloidosis b. For a diagnosis of Non-IgM Monoclonal Gammopathy of Undetermined Significance (MGUS): i. Serum monoclonal protein \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06987708). StuddyBuddy aggregates publicly available trial information.